Next Article in Journal
α-Tocopherol Modulates Non-Amyloidogenic Pathway and Autophagy in an In Vitro Model of Alzheimer’s Disease: A Transcriptional Study
Next Article in Special Issue
Entropy Analysis of High-Definition Transcranial Electric Stimulation Effects on EEG Dynamics
Previous Article in Journal
The Roles of Statistics in Human Neuroscience
Previous Article in Special Issue
Comparison of Transcranial Direct Current Stimulation Electrode Montages for the Lower Limb Motor Cortex
Open AccessArticle

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART

1
Department of Global Health and Infection, Brighton and Sussex Medical School and Brighton and Sussex University Hospitals NHS Trust, London BN1 9PX, UK
2
Chelsea and Westminster NHS Foundation Trust, London SW10 9NH, UK
3
Imperial College London, St Mary’s Campus, London W2 1PG, UK
4
Guy’s and St Thomas’ NHS Trust, London SE1 7EH, UK
*
Author to whom correspondence should be addressed.
Brain Sci. 2019, 9(8), 195; https://doi.org/10.3390/brainsci9080195
Received: 25 June 2019 / Revised: 2 August 2019 / Accepted: 9 August 2019 / Published: 9 August 2019
(This article belongs to the Collection Collection on Clinical Neuroscience)
Objective: Occult central nervous system (CNS) symptoms not recognized by people living with HIV (PLWH) receiving efavirenz or their clinicians could occur and impact people’s quality of life. The aim of this study was to determine whether CNS parameters improve in PLWH when switching from efavirenz to rilpivirine. Methods: PLWH receiving tenofovir disoproxil fumarate, emtricitabine, efavirenz (Atripla™) with undetectable HIV RNA, and no CNS symptoms were switched cART to tenofovir disoproxil fumarate, emtricitabine, rilpivirine (Eviplera™). CNS parameters including sleep, anxiety, and depressive symptoms were evaluated using patient-reported outcome measures at baseline, 4, 12, and 24 weeks after switching therapy. A median CNS score was derived from the sum of CNS toxicities of all the grades collected in the study questionnaires. Cognitive function was assessed using a computerized test battery. Results: Of 41 participants, median age was 47 years, Interquartile range (IQR) 31, 92% were male and 80% were of white ethnicity. A significant reduction in total CNS score (10 to 7) was observed at 4 weeks (p = 0.028), but not thereafter. Significant improvements in sleep and anxiety were observed 4, 12 and 24 weeks after switching therapy (p < 0.05). No significant change in global cognitive scores was observed. Conclusions: Switching from efavirenz to rilpivirine based regimens in virologically suppressed PLWH without perceived CNS symptoms was well tolerated and slightly improved overall CNS symptoms. View Full-Text
Keywords: HIV; efavirenz; rilpivirine; Central nervous system HIV; efavirenz; rilpivirine; Central nervous system
Show Figures

Figure 1

MDPI and ACS Style

Vera, J.H.; Bracchi, M.; Alagaratnam, J.; Lwanga, J.; Fox, J.; Winston, A.; Boffito, M.; Nelson, M. Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sci. 2019, 9, 195.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop